- CDK4/6 INHIBITOR
-
Disclosed is a series of compounds acting as CDK4/6 inhibitors. Specifically disclosed are compounds as represented by formula (I), pharmaceutically acceptable salts or isomers thereof, pharmaceutical compositions containing same, and the use thereof in the preparation of drugs for treating cancers.
- -
-
-
- CERTAIN PROTEIN KINASE INHIBITORS
-
Provided are certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
- -
-
-
- PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS
-
The present invention relates to piperidine and pyrazine derivatives according to formulae (Ia), (Ib) and (II) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.
- -
-
Page/Page column 84-85
(2010/11/03)
-
- Novel CXCR3 antagonists with a piperazinyl-piperidine core
-
High-throughput screening of an encoded combinatorial aryl piperazine library led to the identification of a novel series of potent piperazinyl-piperidine based CXCR3 antagonists. Analogs of the initial hit were synthesized via solid and solution phase me
- McGuinness, Brian F.,Carroll, Carolyn DiIanni,Zawacki, Lisa Guise,Dong, Guizhen,Yang, Cangming,Hobbs, Doug W.,Jacob-Samuel, Biji,Hall III, James W.,Jenh, Chung-Her,Kozlowski, Joseph A.,Anilkumar, Gopinadhan N.,Rosenblum, Stuart B.
-
scheme or table
p. 5205 - 5208
(2010/03/31)
-
- NEW COMPOUNDS
-
The present invention encompassescompounds of general formula (1) wherein R1 to R4 , X and n are defined as in claim 1, which are suitable for the treatment of ailments characterised byexcessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
- -
-
Page/Page column 20
(2008/12/06)
-
- 4,4,5,5, Tetrasubstituted imidazolines
-
There is provided a compound of formula I and the pharmaceutically acceptable salts and esters thereof wherein X1, X2, R1, R2, R3, R4, R5 and R6 are herein described. The compounds exhibit activity as anticancer agents.
- -
-
Page/Page column 21/1
(2008/06/13)
-
- 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
-
In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of
- -
-
-
- Modified aminoacids, pharmaceuticals containing these compounds and method for their production
-
The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4and R11are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.
- -
-
Example A19b)
(2008/06/13)
-
